RYTM News and Press, Rhythm Pharmaceuticals Inc.

2026-06-17 12:02:18 ET Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome June 13, 2026 9:00 AM EDT... Read the full article on Seeking Alpha For further details see: Rhythm Pharmaceuticals, Inc. (...

 -- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- - - Bivamelagon therapy achieved progressive reductions in BMI and hunger measures in patients (N=26) with acquired HO at one year -- -- Real-w...

2026-06-15 11:15:04 ET Paul Matteis from Stifel Nicolaus issued a price target of $133.00 for RYTM on 2026-06-15 13:31:00. The adjusted price target was set to $133.00. At the time of the announcement, RYTM was trading at $94.7336. The overall price target consensus is a...

2026-06-15 07:15:07 ET Wells Fargo analyst issues OVERWEIGHT recommendation for RYTM on June 15, 2026 10:34AM ET. The previous analyst recommendation was Overweight. RYTM was trading at $88.38 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --    -- Positive results reinforce rational...

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast o...

2026-06-08 17:28:31 ET Rhythm Pharmaceuticals, Inc. (RYTM) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 1:20 PM EDT... Read the full article on Seeking Alpha For further details see: Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Goldman Sachs 47...

2026-06-03 02:58:35 ET My optimism about Rhythm Pharmaceuticals ( RYTM ) isn’t based simply on its newly expanded label for the rare disease drug IMCIVREE. I believe the truly compelling thesis here is that Rhythm is building a specialized commercial and clinical platform aro...

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking ...

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driv...